期刊
MOLECULAR PHARMACEUTICS
卷 15, 期 7, 页码 2840-2856出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.8b00336
关键词
glucagon-like peptide-1; type 2 diabetes; lithocholic acid
资金
- National Natural Science Foundation of China [81602964, 81602960, 81703346]
- Natural Science Foundation of Jiangsu Province [BK20150243, BK20161028]
- Science and Technology Support Program of Jiangsu Province [BE2017643]
- PAPD of Jiangsu Higher Education Institutions
- Jiangsu Overseas Visiting Scholar Program for University Prominent Young & Middle-aged Teachers and Presidents
GLP-1 analogs suffer from the main disadvantage of a short in vivo half-life. Lithocholic acid (LCA), one of the four main bile acids in the human body, possesses a high albumin binding rate. We therefore envisioned that a LCA-based peptide delivery system could extend the half-life of GLP-1 analogs by facilitating the noncovalent binding of peptides to human serum albumin. On the basis of our previously identified Xenopus GLP-1 analogs (1-3), a series of LCA-modified Xenopus GLP-1 conjugates were designed (4a-4r), and the bioactivity studies of these conjugates were performed to identify compounds with balanced in vitro receptor activation potency and plasma stability. 4c, 4i, and 4r were selected, and their LCA side chains were optimized to further increase their stability, affording 5a-5c. Compound 5b showed a more increased albumin affinity and prolonged in vitro stability than that of 4i and liraglutide. In db/db mice, 5b exhibited comparable hypoglycemic and insulinotropic activity to liraglutide and semaglutide. Importantly, the enhanced albumin affinity of 5b resulted in a prolonged in vivo antidiabetic duration. Finally, chronic treatment investigations of 5b demonstrated the therapeutic effects of 5b on HbA1c, body weight, blood glucose, and pancreatic endocrine deficiencies on db/db mice. Our studies revealed 5b as a promising antidiabetic candidate. Furthermore, our study suggests the derivatization of Xenopus GLP-1 analogs with LCA represents an effective strategy to develop potent long acting GLP-1 receptor agonists for the treatment of type 2 diabetes.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据